| Table of Contents |  |
|
Case Report
|
| A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml |
| Govarthanan Rajendiran1, Linda Green2, Gurdeep Chhabra3 |
|
1PGY-III Pesident/Chief resident, Dept. of Internal Medicine, Prince George’s Hospital Center, Maryland, USA.
2Assistant program director, Dept. of Internal Medicine, , Prince George’s Hospital Center, Maryland, USA. 3Hemato-oncologist, Prince George’s Hospital Center, Maryland, USA. |
|
doi:10.5348/ijcri-2011-09-55-CR-5
|
|
Address correspondence to: Govarthanan Rajendiran 3001 Hospital Drive J-500, 5th Floor Department of Internal Medicine Cheverly, Maryland USA 20785 Phone: 1-(301) 768-3802 Fax: +1-(301) 618-2986 govdocus@gmail.com |
|
[HTML Full Text]
[PDF Full Text]
|
| How to cite this article: |
| Rajendiran G, Green L, Chhabra G. A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml. International Journal of Case Reports and Images 2011;2(9):16-20. |
|
Abstract
|
|
Introduction:
Bone metastases from prostate cancer are commonly osteoblastic and can result in disabling skeletal complications and affect quality of life. We report a rare case of prostate cancer presenting with diffuse osteolytic metastases.
Case Report: A 65-year-old African American man, with no past medical history or specific urologic symptoms, sought medical attention for non-specific pain symptoms. He had metastatic prostate adenocarcinoma, high PSA level 7242 ng/mL and extensive osteolytic metastases. After a year of therapy with antiandrogens, zoledronic acid and local radiation, patient was asymptomatic and did not suffer disabling skeletal complications. His PSA level has been stable and less than 1 ng/mL. Conclusion: Prostate cancer can rarely present with diffuse osteolytic metastases. Early initiation of of supportive treatment, especially the bisphosphonate Zoledronic Acid, plays a pivotal role in the reduction of disabling skeletal complications. | |
|
Key Words:
Prostate adenocarcinoma, Osteolytic metastases, Androgen deprivation therapy, Skeletal related event, Zoledronic acid
| |
| [HTML Full Text] [PDF Full Text] |
|
Author Contributions:
Govarthanan Rajendiran - Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Linda Green - Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Gurdeep Chhabra - Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published |
|
Guarantor of submission:
The corresponding author is the guarantor of submission. |
|
Source of support:
Nono |
|
Conflict of interest:
Gurdeep Chhabra, Hemato-oncologist, is a speaker for Novartis. Other authors have no financial interests or conflict of interests. |
|
Copyright:
© Govarthanan Rajendiran et al. 2011; This article is distributed the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any means provided the original authors and original publisher are properly credited. (Please see Copyright Policy for more information.) |
|
|